W-L Listerine Anticaries Rinse Gingivitis Assessment Required - FDA
This article was originally published in The Tan Sheet
Executive Summary
Acceptance of plaque reduction as the sole outcome of an experimental gingivitis model conducted to demonstrate the antiplaque/antigingivitis activities of Pfizer/Warner-Lambert's Listerine anticaries mouthrinse would be "premature," FDA tells company.
You may also be interested in...
Listerine With Fluoride Proposed Six-Month Study To Be Reviewed By FDA
Pfizer Consumer Healthcare plans to conduct a six-month clinical study involving at least 300 subjects to determine whether adding .02% sodium fluoride to the company's Listerine mouthrinse affects the antiplaque/ antigingivitis effectiveness of the product
Listerine With Fluoride Proposed Six-Month Study To Be Reviewed By FDA
Pfizer Consumer Healthcare plans to conduct a six-month clinical study involving at least 300 subjects to determine whether adding .02% sodium fluoride to the company's Listerine mouthrinse affects the antiplaque/ antigingivitis effectiveness of the product
Listerine With Fluoride Proposed Six-Month Study To Be Reviewed By FDA
Pfizer Consumer Healthcare plans to conduct a six-month clinical study involving at least 300 subjects to determine whether adding .02% sodium fluoride to the company's Listerine mouthrinse affects the antiplaque/ antigingivitis effectiveness of the product